RNS28 Aug 2025 07:47
From our RNS 3/6/25 this is why we recruited him and he is now going to work FTE at the company, brilliant mind, great things to come.
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, is pleased to announce that Professor David Nutt, who has served as Senior Scientific Advisor to the Company since July 2024, has been appointed to the Company's management team as Chief Scientific Officer ("CSO") with immediate effect.
Professor Nutt is one of the world's foremost authorities in brain science and psychiatric medicine, with a distinguished career spanning more than four decades. He holds the Edmond J. Safra Chair in Neuropsychopharmacology at Imperial College London, where he leads the Neuropsychopharmacology Unit within the Division of Brain Sciences. His research has significantly advanced the understanding and treatment of central nervous system ("CNS") disorders, particularly in addiction, depression, anxiety, and other high-burden mental health conditions.
Professor Nutt has authored over 600 peer-reviewed publications and several landmark texts on psychiatric illness, brain chemistry and CNS drug development. His work has played a pivotal role in translating neuroscience into effective clinical interventions. Professor Nutt is a Fellow of the Royal College of Physicians, the Royal College of Psychiatrists and the Academy of Medical Sciences and has held senior advisory roles with leading UK and European medical research institutions.